免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
黑色素瘤及其他实体瘤的 TIL（肿瘤浸润淋巴细胞）治疗：回顾过去，继续前行
英文原题：Tumor-Infiltrating Lymphocyte Therapy for Melanoma and Other Solid Tumors: Looking Back, Yet Moving Forward.
查看英文原题
Tumor-Infiltrating Lymphocyte Therapy for Melanoma and Other Solid Tumors: Looking Back, Yet Moving Forward.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
Lifileucel是首个在晚期黑色素瘤中获得监管批准的实体瘤过继性TIL（肿瘤浸润淋巴细胞）治疗产品，代表了在利用细胞疗法改善实体瘤患者预后方面的一项关键成就。本综述追溯了过继性TIL疗法从最初的黑色素瘤人体研究，到近期其他实体瘤研究进展的发展历程，并展望了正在进行的和未来的临床前及临床研究领域，以改进这一新型治疗策略。
展开英文摘要原文
Lifileucel, the first solid tumor adoptive tumor infiltrating lymphocyte (TIL) therapy product to receive regulatory approval in advanced melanoma, represents a critical achievement in the pursuit of improving outcomes using cellular therapies in patients with solid tumors.
This review traces the development of adoptive TIL therapy from the initial human studies in melanoma, through recent advances in studies of other solid tumors, and previews ongoing and future areas for preclinical and clinical advances to improve upon this novel therapeutic strategy.
论文信息
- 作者
- Shoushtari AN、Powell DJ
- 单位
- Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York. Electronic address: shoushta@mskcc.org.United States
- 文献类型
- 综述
- 期刊
- Transplantation and cellular therapy2025 Mar
- 原文标识
- PubMed 40089327 · DOI 10.1016/j.jtct.2024.11.017
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →